Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Oncology|May 4, 2019
Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST TrialRosalba Miceli, Jiyeong An, Maria Di Bartolomeo, et al.
British Journal of Cancer|August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trialsAlexej Ballhausen, Federica Morano, Arndt Stahler, et al.
BMC Cancer|April 8, 2025
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trialVincenzo Nasca, Francesca Bergamo, Luisa Foltran, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Scientific Reports|March 1, 2019
Prognostic impact of ATM mutations in patients with metastatic colorectal cancerGiovanni Randon, Giovanni Fucà, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studiesCarlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
International Journal of Cancer|June 9, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trialAlessandra Raimondi, Giovanni Randon, Michele Prisciandaro, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2018
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferaseSarit Schwartz, Chris Szeto, Yuan Tian, et al.
Future Oncology (London, England)|June 12, 2025
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinomaSimone Oldani, Natalie Prinzi, Federica Morano, et al.
The Oncologist|May 6, 2020
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease BurdenFilippo Pietrantonio, Fotios Loupakis, Giovanni Randon, et al.
Pageof 8